Modality
Fusion Protein
MOA
MALT1i
Target
Menin
Pathway
PD-1/PD-L1
PV
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
~May 2023
→ ~Aug 2024
Phase 3
Nov 2024
→ Dec 2031
Phase 3Current
NCT03338925
784 pts·PV
2024-11→2031-12·Completed
784 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-12-055.7y awayPh3 Readout· PV
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Complet…
Catalysts
Ph3 Readout
2031-12-05 · 5.7y away
PV
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03338925 | Phase 3 | PV | Completed | 784 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Sovarelsin | Alnylam | Phase 2/3 | LAG-3 |